BIO Responds To President Obama's State of the Union Speech

WASHINGTON--The Biotechnology Industry Organization (BIO) issued the following statement in response to President Obama's State of the Union speech.

Jim Greenwood, BIO President and CEO:

"Having long advocated a large scale genomics project to help understand the basis of chronic disease, I was pleased to hear President Obama's words about its promise, and look forward to working with the National Institutes of Health (NIH) and Chairman Fred Upton, Congresswoman Diana DeGette, and members of the Energy and Commerce Committee through the 21st Century Cures Initiative and the Senate to develop a study that can revolutionize our understanding of disease.

"A large-scale national research commitment to chronic conditions would identify precursors and early signs of disease or disease risk to unlock the root causes of these conditions that threaten the health of our loved ones and undermine our nation's fiscal health. Our hopes for cures hinge on understanding how to intervene to halt the progress of disease. A critical feature of such an effort is allowing access to study data by researchers in academia, government, and the biopharma industry.

"Biopharma researchers are committed to developing the next generation of modern medicines to transform patient care. The urgency of finding and developing 21st Century Cures cannot be overstated. Biotech holds the greatest promise for finding a cure. Precision medicine – finding the right treatment for the right patient at the right time – can help maximize clinical benefit while reducing the risk of side effects.

"The President also urged reforming the U.S. tax code. We support a tax code that recognizes innovation as a crucial part of the 21st century American economy and helps the U.S. compete more effectively in the global economy. Comprehensive tax reform should lower corporate tax rates, while moving to a territorial system of taxation. Yet comprehensive tax reform should go further to support growth and innovation in biotech companies, most of which are pre-revenue. Furthermore, we will fight to protect the Orphan Drug Tax Credit, which has been instrumental in encouraging innovation into new cures and treatments for rare diseases."

For more information on BIO and the biotechnology industry, please visit http://www.bio.org.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.BIOtechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter.Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO CEO & Investor Conference
February 9-10, 2015
New York City, NY

BIO-Europe Spring
March 9-11, 2015
Paris, France

BIO Asia International Conference
March 24-25, 2015
Tokyo, Japan

BioEquity Europe
May 19-20, 2015
Vienna, Austria

BIO International Convention
June 15-18, 2015
Philadelphia, PA

 

Contacts

Biotechnology Industry Organization
Tracy Cooley, APR
202-312-9274
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech

 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.